Altimmune, Inc., a clinical stage biopharmaceutical company, focuses on developing treatments for obesity and liver diseases. The company's lead product candidate, pemvidutide (proposed INN, formerly known as ALT-801), is a GLP-1/glucagon dual receptor agonist that is in Phase 1b trial for the treatment of obesity and non-alcoholic steatohepatitis. It is also developing HepTcell, an immunotherapeutic product candidate, which is in Phase 2 clinical trial for patients chronically infected with the hepatitis B virus. The company was formerly known as Vaxin Inc. and changed its name to Altimmune, Inc. in September 2015. Altimmune, Inc. was founded in 1997 is headquartered in Gaithersburg, Maryland.
Revenue of Altimmune, Inc. (ALT)
Revenue in 2023 (TTM): $426 K
According to Altimmune, Inc.'s latest financial reports the company's current revenue (TTM) is $426 K. The revenue is the total amount of income that a company generates by the sale of goods or services. Unlike with the earnings no expenses are subtracted.
Revenue history of Altimmune, Inc.
Annual Revenue
| Year | Revenue | Gross Profit | Ebitda | Income Before Tax | Net Income |
|---|---|---|---|---|---|
| 2023 | $426 K | $-65,373,000 | $-87,935,000 | $-88,447,000 | $-88,447,000 |
| 2022 | $-68,000 | $-136,000 | $-84,402,000 | $-84,910,000 | $-84,713,000 |
| 2021 | $4.41 M | $3.86 M | $-96,533,869 | $-97,090,824 | $-96,171,311 |
| 2020 | $8.19 M | $-25,324,291 | $-54,154,020 | $-54,461,501 | $-49,044,477 |
| 2019 | $5.8 M | $-11,264,152 | $-20,189,065 | $-20,578,631 | $-20,520,131 |
| 2018 | $10.33 M | $-8,128,142 | $-44,721,483 | $-45,320,946 | $-39,171,152 |
| 2017 | $41.5 K | $-18,364,826 | $-51,762,607 | $-52,063,765 | $-46,425,390 |
| 2016 | $5.23 M | $-1,991,264 | $-10,912,971 | $205.02 M | $193.85 M |
| 2015 | $10.64 M | $5.58 M | $-3,182,779 | $-3,378,959 | $-3,440,705 |
| 2014 | $10.19 M | $5.93 M | $-9,532,595 | $-9,893,649 | $-9,955,395 |
| 2013 | $17.91 M | $17.91 M | $-11,104,838 | $-11,656,607 | $-11,718,353 |
| 2012 | $25.18 M | $25.18 M | $-4,078,107 | $-4,724,586 | $-4,920,115 |
| 2011 | $24.27 M | $24.27 M | $-3,281,925 | $-3,797,573,000,000 | $-3,797,573 |
| 2010 | $20.99 M | $20.99 M | $-23,256,932 | $-34,849,277,000,000 | $-34,849,277 |
| 2009 | $27.55 M | $27.55 M | $-28,570,159 | $-32,279,760,000 | $-32,279,760 |
| 2008 | $32.91 M | $32.91 M | $-33,027,812 | $-36,415,113,000 | $-36,415,113 |
| 2007 | $14.64 M | $14.64 M | $-15,798,078 | $-13,587,303 | $-13,587,303 |
| 2006 | $1.85 M | $1.85 M | $-14,049,994 | $1.2 M | $1.02 M |
| 2005 | $586.07 K | $471.07 K | $325.3 K | $325.3 K | $277.3 K |